Balance Sheet
Accounts PayablesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Other Non-Current Assets (2016 - 2025)

Viking Therapeutics' Other Non-Current Assets history spans 12 years, with the latest figure at $46000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Assets changed 0.0% year-over-year to $46000.0; the TTM value through Dec 2025 reached $46000.0, changed 0.0%, while the annual FY2025 figure was $46000.0, 0.0% changed from the prior year.
  • Other Non-Current Assets for Q4 2025 was $46000.0 at Viking Therapeutics, roughly flat from $46000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $46000.0 in Q3 2024 and bottomed at $33000.0 in Q4 2021.
  • The 5-year median for Other Non-Current Assets is $33000.0 (2021), against an average of $37588.2.
  • The largest annual shift saw Other Non-Current Assets changed 0.0% in 2022 before it surged 39.39% in 2024.
  • A 5-year view of Other Non-Current Assets shows it stood at $33000.0 in 2021, then changed by 0.0% to $33000.0 in 2022, then changed by 0.0% to $33000.0 in 2023, then surged by 39.39% to $46000.0 in 2024, then changed by 0.0% to $46000.0 in 2025.
  • Per Business Quant, the three most recent readings for VKTX's Other Non-Current Assets are $46000.0 (Q4 2025), $46000.0 (Q3 2025), and $46000.0 (Q2 2025).